Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
TriSalus Life Sciences Inc. (TLSIW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: TLSIW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -54.53% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.47 | 52 Weeks Range 0.42 - 2.25 | Updated Date 06/10/2025 |
52 Weeks Range 0.42 - 2.25 | Updated Date 06/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -84.67% | Operating Margin (TTM) -79.95% |
Management Effectiveness
Return on Assets (TTM) -85.52% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 29370602 |
Shares Outstanding - | Shares Floating 29370602 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
TriSalus Life Sciences Inc.
Company Overview
History and Background
TriSalus Life Sciences, Inc. is a commercial-stage medical device company founded in 2009 and focused on developing and commercializing disruptive technologies to treat liver and pancreatic tumors. It went public on January 26, 2024, and is relatively new to the public market.
Core Business Areas
- Drug Delivery Systems: TriSalus develops and markets the TriNav Infusion System, designed to deliver drugs directly to tumors in the liver and pancreas.
- Immunotherapeutic Platform: The company is developing its therapeutic platform, including investigational drugs designed to modulate the tumor microenvironment and enhance the immune response against tumors.
Leadership and Structure
Mary Szela serves as the Chief Executive Officer. The company has a board of directors and a management team overseeing various functions like research and development, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- TriNav Infusion System: A pressure-enabled drug delivery system designed to improve the penetration of therapeutics into solid tumors of the liver and pancreas. There is no reliable market share data available as it is a niche product, but the market potential is driven by the number of patients with liver and pancreatic tumors. Competitors include companies offering standard drug delivery methods like catheters and embolization agents.
- SD-101 (Investigational): An investigational TLR9 agonist being evaluated for its potential to stimulate an immune response against tumors when delivered via the TriNav Infusion System. There is no market share as it's under development. Potential competitors in the immunotherapy space include companies developing checkpoint inhibitors and other immunomodulatory agents.
Market Dynamics
Industry Overview
The industry encompasses interventional oncology and drug delivery systems targeting solid tumors, specifically in the liver and pancreas. This includes targeted therapies, immunotherapies, and localized drug delivery methods.
Positioning
TriSalus Life Sciences is positioned as a developer of innovative drug delivery systems and immunotherapeutics, with a focus on enhancing the efficacy of cancer treatments for liver and pancreatic tumors. Its competitive advantage lies in its proprietary pressure-enabled drug delivery technology.
Total Addressable Market (TAM)
The TAM for liver and pancreatic cancer treatment is significant, estimated in the billions of dollars, driven by the high prevalence and poor prognosis of these cancers. TriSalus is targeting a specific segment of this market with its innovative drug delivery and immunotherapeutic approaches.
Upturn SWOT Analysis
Strengths
- Proprietary pressure-enabled drug delivery technology (TriNav)
- Focus on difficult-to-treat liver and pancreatic tumors
- Potential for synergistic effect with immunotherapies (SD-101)
- Experienced management team
- FDA Clearance for device
Weaknesses
- Limited commercial history as a public company
- Dependence on the success of clinical trials for SD-101
- Relatively small company size compared to major players
- Requires substantial capital to fund operations
Opportunities
- Expansion of TriNav Infusion System into new indications
- Successful clinical development and commercialization of SD-101
- Strategic partnerships with pharmaceutical companies
- Increasing adoption of targeted therapies and immunotherapies in cancer treatment
- Growth in interventional oncology procedures
Threats
- Competition from established medical device and pharmaceutical companies
- Regulatory hurdles and potential delays in clinical trials
- Unfavorable reimbursement policies
- Technological advancements by competitors
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- BSX
- MRK
- JNJ
Competitive Landscape
TriSalus faces competition from established medical device companies and pharmaceutical companies with larger resources and broader product portfolios. Its innovative technology and focus on specific cancer types provide a competitive edge. However, scaling its operations and securing market share will be challenging.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is limited due to the company's recent IPO.
Future Projections: Future growth is dependent on the successful commercialization of the TriNav Infusion System, the clinical development of SD-101, and expansion into new indications. Analyst estimates may vary.
Recent Initiatives: Recent initiatives include expanding the commercial team for TriNav, advancing clinical trials for SD-101, and building strategic partnerships.
Summary
TriSalus Life Sciences is an early-stage company with innovative technology targeting liver and pancreatic cancers. Its strength lies in its unique drug delivery system and immunotherapeutic potential. Challenges include its limited commercial history, dependence on clinical trial outcomes, and competition from larger companies. The company's success hinges on its ability to successfully commercialize its products and expand into new markets.
Peer Comparison
Sources and Disclaimers
Data Sources:
- TriSalus Life Sciences Inc. SEC Filings
- Company Website
- Analyst Reports
- Third Party Financial Data Providers
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About TriSalus Life Sciences Inc.
Exchange NASDAQ | Headquaters Westminster, CO, United States | ||
IPO Launch date 2023-08-11 | CEO, President & Director Ms. Mary T. Szela B.S.N., M.B.A. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 110 | Website https://trisaluslifesci.com |
Full time employees 110 | Website https://trisaluslifesci.com | ||
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. The company was founded in 2009 and is headquartered in Westminster, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.